A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes
about
The serpin proteinase inhibitor 9 is an endogenous inhibitor of interleukin 1beta-converting enzyme (caspase-1) activity in human vascular smooth muscle cellsCirculating serpin tumor markers SCCA1 and SCCA2 are not actively secreted but reside in the cytosol of squamous carcinoma cellsNucleocytoplasmic distribution of the ovalbumin serpin PI-9 requires a nonconventional nuclear import pathway and the export factor Crm1Induction of serine protease inhibitor 9 by Mycobacterium tuberculosis inhibits apoptosis and promotes survival of infected macrophagesDiscriminating between the activities of human neutrophil elastase and proteinase 3 using serpin-derived fluorogenic substratesIntracellular serine protease inhibitor SERPINB4 inhibits granzyme M-induced cell deathMyxoma virus Serp2 is a weak inhibitor of granzyme B and interleukin-1beta-converting enzyme in vitro and unlike CrmA cannot block apoptosis in cowpox virus-infected cellsCaspase-1 (interleukin-1beta-converting enzyme) is inhibited by the human serpin analogue proteinase inhibitor 9Update of the human and mouse SERPIN gene superfamilyThe serine proteinase inhibitor (serpin) plasminogen activation inhibitor type 2 protects against viral cytopathic effects by constitutive interferon alpha/beta primingThe major human and mouse granzymes are structurally and functionally divergentAn overview of the serpin superfamilyCell biological steps and checkpoints in accessing NK cell cytotoxicitySerine proteinase inhibitor 9 can be recognized by cytotoxic T lymphocytes of epithelial cancer patientsGranzyme M is a regulatory protease that inactivates proteinase inhibitor 9, an endogenous inhibitor of granzyme BA natural genetic variant of granzyme B confers lethality to a common viral infectionIdentification and characterization of a novel rat ov-serpin family member, trespinImmunotherapeutic targeting of membrane Hsp70-expressing tumors using recombinant human granzyme BAlveolar epithelial cell chemokine expression triggered by antigen-specific cytolytic CD8(+) T cell recognition.Type II pneumocyte-CD8+ T-cell interactions. Relationship between target cell cytotoxicity and activation.A new intracellular serine protease inhibitor expressed in the rat pituitary gland complexes with granzyme B.SRP-2 is a cross-class inhibitor that participates in postembryonic development of the nematode Caenorhabditis elegans: initial characterization of the clade L serpins.Protection of hepatocytes from cytotoxic T cell mediated killing by interferon-alpha.Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonistsRegulation of pro-apoptotic leucocyte granule serine proteinases by intracellular serpins.The granzyme B-Serpinb9 axis controls the fate of lymphocytes after lysosomal stress.Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathwayIdentification of a nuclear targeting domain in the insertion between helices C and D in protease inhibitor-10.Identification of centerin: a novel human germinal center B cell-restricted serpin.Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors.Granzyme A activates another way to dieDelivery and therapeutic potential of human granzyme B.Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.Serpinb9 (Spi6)-deficient mice are impaired in dendritic cell-mediated antigen cross-presentation.Discordant regulation of granzyme H and granzyme B expression in human lymphocytes.Validation of noninvasive diagnosis of BK virus nephropathy and identification of prognostic biomarkers.Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potencyIntracellular serpins in haemopoietic and peripheral blood cells.Death by a thousand cuts: granzyme pathways of programmed cell deathPerforin deficiency and susceptibility to cancer.
P2860
Q22254013-57772B82-B2A1-448F-B7B8-959B9A766188Q24290134-EEF7F1A2-AAA5-48A9-9C94-CD6FB58892DCQ24291464-FD352ECC-9E1B-4221-9F32-5B16A6EE6E84Q24297607-9594F918-A082-426E-8C47-2A445D17F584Q24301375-F73FB54C-BD7C-4365-9257-42EAC65E3183Q24324387-A5B57536-C6F6-49D6-A23F-D9739A934011Q24527273-54D3BB66-0F62-4E17-88E9-DDAF69881571Q24531784-1BE9FB3A-A9CB-49E9-A6DD-AC3E2EC2FA23Q24622280-67945E41-434F-46C4-97AC-D6A71A500B18Q24647186-6358A5F2-3313-4D6E-9917-2F2C4F8820D3Q24682724-88DCE2FB-71C3-469E-9D1C-0CAAC9757144Q24684030-AC6563EC-4B21-4E96-AF8F-4B3063FECD16Q26852411-E0B716B2-94F1-4021-A950-CFEDA5E77940Q28202640-3123386E-BEA9-4671-9740-31987F8576B4Q28288671-F58BD82B-AA72-4ADA-95EF-E79C7923BBC6Q28542688-222E82D6-2F4E-44FB-B4A0-8A2E974DF777Q28572904-E7758468-2F96-4DA7-A0E5-2DDB2D1B30DDQ28729023-41CB254C-C92B-4E7F-A6DC-B44592B0D839Q30306117-A8F0F4AE-5582-4AED-A20F-D8446735BAE6Q30308011-A1BAEEF9-1350-455D-8C3C-6115D6130D11Q31942742-D404459D-3C39-4BCC-BDE6-111DCDDDB48BQ33197028-C5603FC7-1986-4AF5-A820-0F4498C287A2Q33295380-D82753C4-8FB5-4EF4-8A99-C95831A21A09Q33302568-D12DB4DA-441A-4BAA-952A-10E9C063DBEBQ33547789-0A8C83E4-82D1-4A48-B904-D86D4B013D91Q33580163-15D99040-7F90-4F66-8A5A-91499CFF47EEQ33781431-201F523F-4F44-4C65-BBB2-C73476152765Q33858163-FF237A97-E22D-43FF-B875-D87FA6553D78Q33924508-FEF9C4FE-FB90-4285-9322-9E0E15FFD472Q33944674-BA20DB41-FCFB-4F12-87DF-76A4C00487C4Q34002316-3BC3BFD0-8735-4564-ABA9-A5A5D2945B70Q34120062-CE0A0905-2A91-4480-BCCF-EB31C8734033Q34149948-369DA2C7-03FB-40D7-B755-5D0C0698917FQ34288486-676C5460-281D-459A-8C73-5CDB345CB87EQ34311596-4E756E22-8225-4D8A-800A-98EEB3914CDCQ34337472-2D842078-3EDC-4B20-890A-D15A9A1CF77EQ34338958-5BFD8E9B-DDF7-42CE-820E-0F1D3940A4E2Q34530137-CDB64F3D-9366-49BC-82E7-D1EB6F8CBE8AQ34588821-F1C2A4C4-11BA-4C87-AF57-042487BC1EBAQ34615774-4DFF5616-510D-4EB4-86EF-5CF1FDBF97A9
P2860
A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes
description
1996 nî lūn-bûn
@nan
1996 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
A cytosolic granzyme B inhibit ...... esent in cytotoxic lymphocytes
@ast
A cytosolic granzyme B inhibit ...... esent in cytotoxic lymphocytes
@en
A cytosolic granzyme B inhibit ...... esent in cytotoxic lymphocytes
@en-gb
A cytosolic granzyme B inhibit ...... esent in cytotoxic lymphocytes
@nl
type
label
A cytosolic granzyme B inhibit ...... esent in cytotoxic lymphocytes
@ast
A cytosolic granzyme B inhibit ...... esent in cytotoxic lymphocytes
@en
A cytosolic granzyme B inhibit ...... esent in cytotoxic lymphocytes
@en-gb
A cytosolic granzyme B inhibit ...... esent in cytotoxic lymphocytes
@nl
prefLabel
A cytosolic granzyme B inhibit ...... esent in cytotoxic lymphocytes
@ast
A cytosolic granzyme B inhibit ...... esent in cytotoxic lymphocytes
@en
A cytosolic granzyme B inhibit ...... esent in cytotoxic lymphocytes
@en-gb
A cytosolic granzyme B inhibit ...... esent in cytotoxic lymphocytes
@nl
P2093
P2860
P921
P3181
P356
P1476
A cytosolic granzyme B inhibit ...... esent in cytotoxic lymphocytes
@en
P2093
L McDonald
P B Coughlin
T A De Jong
P2860
P304
27802-27809
P3181
P356
10.1074/JBC.271.44.27802
P407
P577
1996-11-01T00:00:00Z